Here are six observations:
1. The blinded, randomized clinical trial compared outcomes of cervical fusion between Amedica’s composite silicon nitride devices manufactured with a core of cancellous structured ceramic to the existing standard: PEEK spacers filled with bone autograft.
2. The CASCADE study divided the participants into two groups — one treated with Amedica’s composite silicon nitride devices and the other with PEEK.
3. The study showed comparable clinical and radiographic performance between porous silicon nitride and bone autograft.
4. The FDA previously confirmed that it would review the product as a medical device.
5. The federal agency has 90 days in which to either clear the Class II device for commercial distribution or to seek additional information.
6. Amedica is a medical technology company focused on the development and application of medical-grade silicon nitride ceramics.
More articles on devices:
Interventional Spine’s new Opticage receives FDA clearance: 5 takeaways
Materialise receives FDA clearance for hip guide system
EOS imaging system installed in Japan: 3 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
